Activity Update: structured offering of AI Solutions in
oncological imaging and initial successful deployments
Montpellier, France, June 5th, 2025, 6:00pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert
in AI-enhanced medical imaging solutions that facilitate and secure diagnostics, decision-making, and therapeutic
follow-up, provides an update on its activities two months after announcing its strategic roadmap 1.


Three product ranges structured around Artificial Intelligence (AI), recognized for
their high clinical value
• Myrian®, an advanced visualization platform natively integrating AI
Myrian® is a multi-modality, manufacturer-agnostic advanced visualization software offering a comprehensive
suite with 18 applications dedicated to each specialty. Featuring clinical tools and AI algorithms for prostate, lung
and brain pathologies, Myrian® enables fast and efficient analysis of radiological exams, saving considerable time.
To ensure optimal performance and stay at the forefront of technology, regular updates are carried out. In April
2025, the company obtained CE certification for version 2.14. The Myrian® platform is used by private and public
radiologists and is regulatory certified in nearly 40 countries.

« We have recently integrated Myrian® in our practice. It is a system reliable and user friendly and it was easy to get
used to its many functionalities. Myrian® is a step ahead for our productivity and, most importantly, for the quality of
our patients' care », says Dr. Marcello Palazzotto, Center for Medicine and Radiology Palazzotto, Sciacca, Italy. This
technological choice was made possible thanks to our collaboration with Guerbet Italy, as part of its distribution
agreement for Myrian®.

• DUOnco™, a range of autonomous AI dedicated to oncology
As part of their collaboration, Guerbet and Intrasense recently launched DUOnco™, an AI software suite that
automatically detects lesions in CT scans (thorax-abdomen-pelvis). The range offers two specialized solutions:
DUOnco™ Liver for focal lesions and DUOnco™ Bone for bone lesions. These autonomous models, integrated into
the radiologists' workflow, stand out for their ability to reduce missed lesions and ensure faster and more precise
clinical decision-making.
After obtaining CE marking for focal lesions in 2024, Intrasense also obtained CE certification in March 2025 for
the automatic detection of bone lesions. The company is currently working on certifying a version dedicated to the
pancreas, which has already received “breakthrough designation” status in the United States by the FDA in March
2025.

« In our practice, the evaluation of bone metastases is a critical step that requires great precision due to the
complexity of the examinations. DUOnco™ Bone provides valuable support by optimizing our analysis of CT scan
images and facilitating our decision-making. With this intelligent assistance, we have a tool that improves our
efficiency and directly contributes to optimizing the care pathway in oncology », says Prof. Lassau, university
professor and hospital practitioner in radiology at Paris-Saclay University, radiologist at Gustave Roussy.

1Read March 26 press release, « Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive
tomorrow's growth »




Press release 1/3
• Liflow®, a longitudinal follow-up solution in oncology
Liflow® is the first automated solution for oncological monitoring on CT-TAP scans. Liflow®, enhanced with AI for
lungs, liver, and bones, enables rapid and precise analysis of oncological imaging examinations. Liflow ® is an
innovative solution that continuously evolves to achieve its ambitious goal: reducing the interpretation time of CT-
TAP examinations by 50%. At the end of 2024, Intrasense announced the CE certification of Liflow ® 2.0.
Furthermore, the company has already presented version 3.0, which is currently under development at major
events. This latest evolution should be available by the end of the first half of the year.

« To integrate AI into the care process, we need to create a tool that is not single-task but assists the radiologist in
their complex interpretation work. The analysis of a CT-TAP scan in oncology is long and tedious; Liflow®
significantly reduces the time needed to interpret the data while improving performance, which is a real change today
», says Prof. Aubé, university professor and practitioner, Head of the Radiology Department at Angers University
Hospital.

Through its three product ranges, Intrasense supports patients throughout all stages of their medical
journey, from advanced visualization to lesion detection and oncological monitoring. This comprehensive
AI-driven care is unique in the world and brings considerable gains in decision-making for professionals
in the field.


Visibility and business opportunities at French and international congresses
To consolidate its leading position in AI solutions applied to oncology imaging, Intrasense has intensified its
participation in major congresses and events over the 1st half of 2025, in close collaboration with Guerbet.
These strategic gatherings offer the opportunity to present the latest innovations and exchange views with
customers and industrial partners.
These event include:
- ECR (European Congress of Radiology)- Austria,
- Journées Unicancer - France,
- JPR (Jordana Paulista de Radiologia) - Brazil,
- Journée de Printemps de la SIT (Société Imagerie Thoracique) – France,
- RöKo (German Congress of Radiology) – Germany,
- Conférence AI in Oncology organized by IHU Prism - France


The collaboration with Guerbet has been a strategic lever to maximize the commercial impact of these events. By
combining Intrasense's expertise in medical imaging with Guerbet's commercial network, the company enhances
its visibility among the main players in the sector. This alliance enables the implementation of joint marketing
actions, integrated product demonstrations, and targeted exchanges with opinion leaders, thus offering a
comprehensive and coherent approach to customers and partners, while affirming a common commitment to
medical innovation.




Press release 2/3
“Intrasense's offer enables healthcare professionals to increase productivity, improve diagnostic reliability and
optimize therapeutic follow-up. The user experience is also at the heart of our concerns.
By combining advanced visualization, automated detection and longitudinal lesion tracking, our three product ranges
provide complete coverage of the oncology patient pathway.
Our solutions can be easily integrated into existing workflows and adapted to the organization of care, while
guaranteeing a tangible return on investment in terms of medical time, quality of care and clinical standardization.
This modular approach, combined with a strong field orientation and continuous product improvement, positions
Intrasense as a trusted technology partner for healthcare facilities and manufacturers alike. Jerome Thiebaud, Chief
Business Officer.

In the second half of the year, and as every year, Intrasense will be taking part in the following major events:
- JFR (Journées Francophones de Radiologie) – France
- RSNA (Radiology Conference & Annual Meeting) - USA




About Intrasense
A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense
designs medical imaging software solutions natively enriched by artificial intelligence algorithms.
Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and
simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers
an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a
dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of
cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with
high medical value tools, facilitating analysis, diagnosis and patient management. More information on
www.intrasense.fr


Contacts
INTRASENSE SEITOSEI.ACTIFIN
Communication officer Analyst & Investor Relations
Salomé Sylvestre Foucauld Charavay
Phone : +33 4 67 13 01 30 Phone : +33 6 37 83 33 19
investisseurs@intrasense.fr intrasense@seitosei-actifin.com

Press Relations
Isabelle Dray
Phone : +33 1 56 88 11 29
isabelle.dray@seitosei-actifin.com




Press release 3/3